These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 24692550

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Characterization of chemically modified oligonucleotides targeting a pathogenic mutation in human mitochondrial DNA.
    Tonin Y, Heckel AM, Dovydenko I, Meschaninova M, Comte C, Venyaminova A, Pyshnyi D, Tarassov I, Entelis N.
    Biochimie; 2014 May; 100():192-9. PubMed ID: 23994754
    [Abstract] [Full Text] [Related]

  • 3. MitoTALEN: A General Approach to Reduce Mutant mtDNA Loads and Restore Oxidative Phosphorylation Function in Mitochondrial Diseases.
    Hashimoto M, Bacman SR, Peralta S, Falk MJ, Chomyn A, Chan DC, Williams SL, Moraes CT.
    Mol Ther; 2015 Oct; 23(10):1592-9. PubMed ID: 26159306
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Mitochondrial DNA diseases and therapeutic strategies].
    Tonin Y, Entelis N.
    Med Sci (Paris); 2014 Dec; 30(12):1101-9. PubMed ID: 25537040
    [Abstract] [Full Text] [Related]

  • 7. Rapid directional shift of mitochondrial DNA heteroplasmy in animal tissues by a mitochondrially targeted restriction endonuclease.
    Bayona-Bafaluy MP, Blits B, Battersby BJ, Shoubridge EA, Moraes CT.
    Proc Natl Acad Sci U S A; 2005 Oct 04; 102(40):14392-7. PubMed ID: 16179392
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Parkin overexpression selects against a deleterious mtDNA mutation in heteroplasmic cybrid cells.
    Suen DF, Narendra DP, Tanaka A, Manfredi G, Youle RJ.
    Proc Natl Acad Sci U S A; 2010 Jun 29; 107(26):11835-40. PubMed ID: 20547844
    [Abstract] [Full Text] [Related]

  • 13. Mitochondrial DNA heteroplasmy in disease and targeted nuclease-based therapeutic approaches.
    Nissanka N, Moraes CT.
    EMBO Rep; 2020 Mar 04; 21(3):e49612. PubMed ID: 32073748
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [MITO-Porter; a cutting-edge technology for mitochondrial gene therapy].
    Furukawa R, Yamada Y, Harashima H.
    Yakugaku Zasshi; 2012 Mar 04; 132(12):1389-98. PubMed ID: 23208046
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.